

organized by:



in collaboration with:



under the auspices of:



# IMMUNOTHERAPY bridge 2021

Virtual meeting  
December 1<sup>st</sup> - 2<sup>nd</sup>

# 2021



# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

This year the registration will be **free of charge** for all HCPs, but only registered attendees will be admitted to the meeting.

To register:

- go to: [www.melanomabridge.org/registration-key-dates.php](http://www.melanomabridge.org/registration-key-dates.php) and click on REGISTER NOW
- directly through the link: [www.vincentonair.com](http://www.vincentonair.com)

Please, contact the Organizing Secretariat for any further information:  
[registration@melanomabridge.org](mailto:registration@melanomabridge.org)

# SCIENTIFIC RATIONAL

---

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, kidney, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then two "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No
- Intralesional therapy: oncolytic virus vs other specific immune modulators
- Can vaccine transform cold into hot tumors? Yes or No
- Do early surrogates correlate with long-term overall survival? Yes or No
- Data science approaches to gain insights in to IO development: broad vs deep analytics.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of immunotherapy and based on the increasing success of "Immunotherapy Bridge" events over the years, a panel of international faculty will join the congress that will be held as webinar in December 2021.

Presidents of the Congress are Paolo A. Ascierto (National Cancer Institute, "Fondazione G. Pascale", Naples, Italy), Bernard A. Fox (Earle A. Chiles Research Institute at Providence Cancer Center, Portland, OR, US), Patrick Hwu (Moffitt Cancer Center, Tampa, FL, US) and Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, NY, US), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of the immunotherapy of cancer.

# SCIENTIFIC PROGRAM

Wednesday, Dec 1<sup>st</sup>, 2021



10:30 am	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SITC SESSION</b> <b>LESSONS LEARNED FROM CELL THERAPIES</b> <i>Chairpersons:</i> <b>Bernard A. Fox, Patrick Hwu</b>
10:40 am	CAR-T <b>Chrystal Paulos</b>
10:55 am	Targeting solid malignancies with 'public' neoantigen-specific T cell receptors <b>Christopher Klebanoff</b>
11:10 am	Harnessing the power of a natural killer: bringing NK cells to immuno-oncology <b>Tamara Laskowski</b>
11:25 am	Understanding resistance to develop better CAR T immunotherapies <b>Marco Ruella</b>
11:40 am	Best of SITC 2021 for clinical development and trials <b>Paolo A. Ascierto</b>
11:55 am	Discussion
12:25 pm	LECTURE - Immunotherapy in Renal Cell Carcinoma: update and new perspectives <i>Chairperson:</i> <b>Paolo A. Ascierto</b> <i>Speaker:</i> <b>Giuseppe Procopio</b>
12:55 pm	Lunch**
01:45 pm	<b>SYMPOSIUM</b> - Combinations therapy across cancers <i>Chairperson:</i> <b>Paolo A. Ascierto</b> NSCLC, <b>Cesare Gridelli</b> - RCC, <b>Camillo Porta</b> - Melanoma, <b>Paolo A. Ascierto</b>
	<b>SESSION 2</b> <b>TRENDS IN IMMUNOTHERAPY</b> <i>Chairpersons:</i> <b>John B. Haanen, Sandro Pignata</b>
02:35 pm	Integrating Head and Neck Cancer Immunotherapy into Locally Advanced Treatment <b>Robert L. Ferris</b>
02:50 pm	Pancreatic Cancer <b>Elizabeth Jaffee</b>
03:05 pm	Kidney Cancer <b>Sergio Bracarda</b>

# SCIENTIFIC PROGRAM

Wednesday, Dec 1<sup>st</sup>, 2021



03:20 pm	GI cancer <b>Antonio Avallone</b>
03:35 pm	Implications of the Tumor Microenvironment for Breast Cancer Immunotherapy <b>Leisha A. Emens</b>
03:50 pm	Ovarian Cancer <b>Sandro Pignata</b>
04:05 pm	<i>Coffee Break**</i>
04:20 pm	PDI-blockade for Hodgkin Lymphoma: results, challenges and opportunities <b>Antonio Pinto</b>
04:35 pm	Lecture: Merkel Cell Carcinoma <b>Paolo A. Ascierto</b>
04:50 pm	Discussion
	<b>GREAT DEBATE SESSION</b> <i>Chairpersons: Paolo A. Ascierto, Bernard A. Fox, Patrick Hwu, Igor Puzanov</i>
05:20 pm	Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No <b>Wolf Fridman, Tullia Bruno</b>
05:50 pm	Discussion
06:00 pm	Intralesional therapy: oncolytic virus VS other specific immune modulators <b>Igor Puzanov, Omid Hamid</b>
06:30 pm	Discussion
06:40 pm	Do early surrogates correlate with long-term overall survival? Yes or No <b>Michael A. Postow, Jeffrey Sosman</b>
07:10 pm	Discussion

# SCIENTIFIC PROGRAM

Thursday, Dec 2<sup>nd</sup>, 2021



## SESSION 3 DRIVERS OF IMMUNE RESPONSES

*Chairpersons:* **Alfredo Budillon, Bernard A. Fox**

09:00 am	Biotechnology tricks to harness CD137 (4-1BB) costimulation for cancer immunotherapy <b>Ignacio Melero Bermejo</b>
09:15 am	Super CD8-T cells, a new tool in immunotherapy; T cell reprogramming <b>Samir N. Khleif</b>
09:30 am	Immunotherapy for non-immunogenic tumors <b>Nina Bhardwaj</b>
09:45 am	Role of dendritic cells in immune response <b>Joshua Brody</b>
10:00 am	Pre-existing immune contexture for immunotherapy response <b>Jerome Galon</b>
10:15 am	T-cell regulome in immune checkpoint inhibition <b>Tomas Kirchhoff</b>
10:30 am	Discussion
10:45 am	Coffee Break**
10:55 am	Predicting and mapping tumor regression following neoadjuvant immunotherapy <b>Janis M. Taube</b>
11:10 am	The virtual molecular tumor board as a tool for the delivery of precision oncology <b>Carlo Bifulco</b>
11:25 am	A new perspective on therapy-modulated tumor antigenicity <b>Sandra Demaria</b>
11:40 am	Cancer vaccine concepts for solving infectious diseases <b>Luigi Buonaguro</b>
11:55 am	PDL1 and IDO targeting vaccination for treatment of metastatic cancer <b>Inge Marie Svane</b>
12:10 pm	Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC
12:25 pm	<b>SYMPOSIUM</b> - Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC <i>Chairperson:</i> <b>Paolo A. Ascierto</b> <b>Paolo A. Ascierto, Dirk Schadendorf</b>

# SCIENTIFIC PROGRAM

Thursday, Dec 2<sup>nd</sup>, 2021



01:15 pm *Lunch\*\**

## **GREAT DEBATE SESSION**

*Chairpersons:* **Paolo A. Ascierto, Bernard Fox, Igor Puzanov**

02:00 pm Can vaccine transform cold into hot tumors? Yes or No  
**Olivera J. Finn, Lisa H. Butterfield**

02:30 pm Discussion

02:40 pm Data science approaches to gain insights in to IO development:  
broad vs deep analytics  
**Theresa LaVallee, Andrew Futreal**

03:10 pm Discussion

03:20 pm *Coffee Break\*\**

## **SESSION**

### **NEO ADJUVANT IMMUNOTHERAPY ACROSS CANCERS**

*Chairpersons:* **Paolo A. Ascierto, Elizabeth Burton**

03:30 pm Overview and GU cancer  
**Padmanee Sharma**

03:45 pm Breast Cancer  
**Elizabeth Mittendorf**

04:00 pm Colon cancer  
**Myriam Chalabi**

04:15 pm NSCLC  
**Tina Cascone**

04:30 pm Melanoma  
**Rodabe Amaria**

04:45 pm NMSC as Model for Neoadjuvant Immunotherapy  
**Neil Gross**

05:00 pm Refining pathological response assessment in neoadjuvant therapy for melanoma  
**Richard Scolyer**

05:15 pm Discussion

05:45 pm Conclusions  
**Paolo A. Ascierto, Bernard Fox, Igor Puzanov**

2021



# PRESIDENCY

---

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Igor Puzanov**

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

# SCIENTIFIC BOARD

**Sanjiv S. Agarwala**

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, PA, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Carlo Bifulco**

Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Lisa H. Butterfield**

Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

**Elizabeth M. Burton**

Executive Director, Strategic Translational Research Initiative Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York, NY, US

# SCIENTIFIC BOARD

---

**Reinhard Dummer**

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Claus Garbe**

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

**Omid Hamid**

Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, CA, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Giuseppe Masucci**

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

**Iman Osman**

Rudolf L. Baer MD Professor of Dermatology, Departments of Medicine (Oncology) and Urology, Director Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

**Giuseppe Palmieri**

President, Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael A. Postow**

Memorial Sloan Kettering Cancer Center, New York, NY, US

**Igor Puzanov**

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

**Tara Withington**

Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

# FACULTY

**Rodabe Amaria**

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

# FACULTY

---

**Avallone Antonio**

MD, SC of Abdominal Medical Oncology, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Nina Bhardwaj**

Director of Immunotherapy, Waldman Chair in Cancer Research, Professor of Medicine, Hematology and Medical Oncology, The Tisch Cancer Institute, New York, NY, US

**Carlo Bifulco**

Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Sergio Bracarda**

Director, Department of Oncology and Medical & Translational Oncology Unit, Azienda Ospedaliera Santa Maria, Terni, Italy

**Joshua Brody**

Director, Lymphoma Immunotherapy Program ICAHN, School of Medicine at The Mount Sinai Cancer Center, New York, NY, US

**Tullia Bruno**

Assistant Professor, UPMC Hillman Cancer Center, Pittsburgh, PA, US

**Alfredo Budillon**

Chief, Experimental Pharmacology Unit, Department of Translational Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Luigi Buonaguro**

Director, Innovative Immunological Models Department of Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Elizabeth M. Burton**

Executive Director, Strategic Translational Research Initiative Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Lisa H. Butterfield**

Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

**Tina Cascone**

Graduate School of Biomedical Sciences, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Myriam Chalabi**

Medical Oncologist, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York City, NY, US

**Leisha A. Emens**

Professor of Medicine, Director of Translational Immunotherapy for Women's Cancer Research Center, UPMC Hillman Cancer Center/Magee Women's Hospital, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, Pittsburgh, PA, US

**Robert L. Ferris**

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research, Co-Director, Tumor Microenvironment Center Professor of Otolaryngology, of Immunology, and of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, US

# FACULTY

---

**Olivera J. Finn**

Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, US

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Wolf H. Fridman**

Director Cordeliers Research Centre, Paris, France

**Andrew Futreal**

Professor and Chair, Department of Genomic Medicine, The University of Texas Anderson Cancer Center, Houston, TX, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Cesare Gridelli**

Chief of Division of Medical Oncology, "San Giuseppe Moscati" Hospital, Avellino, Italy

**Neil Gross**

Director, Clinical Research, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, US

**John B. Haanen**

Consultant Medical Oncologist, CSO Immunotherapy and Staff Scientist in the Division of Immunology, Professor of Translational Immunotherapy of Cancer, Leiden University Medical Centre, Amsterdam, The Netherlands

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Elizabeth Jaffee**

The Dana and Albert "Cubby" Broccoli, Professor of Oncology, Deputy Director, Sidney Kimmel Cancer Center at Johns Hopkins, Co-Director, Gastrointestinal Cancers Program, Baltimore, MD, US

**Samir N. Khleif**

Director of the Loop Immuno-Oncology Laboratory, Biomedical Scholar and Professor of Oncology, Georgetown University Medical School, Washington DC, US

**Tomas Kirchhoff**

Associate Professor, Perlmutter Cancer Center, New York, NY, US

**Christopher Klebanoff**

Head, Breast Immunotherapy Section, Memorial Sloan Kettering Cancer Center, New York, NY, US

**Tamara Laskowski**

Senior Director, Head of New Therapeutic Products - Personalized Medicine, Lonza Global

**Theresa LaVallee**

Vice President, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy, San Francisco, CA, US

**Ignacio Melero Bermejo**

Hepatology and Gene Therapy, Center for Applied Medical Research, University of Navarra, Spain

**Elizabeth Mittendorf**

Robert and Karen Hale Distinguished Chair in Surgical Oncology, Associate Chair for Research, Department of Surgery at Brigham and Women's Hospital, Director of Breast Immuno-Oncology program and Co-Director of Breast Cancer Clinical Research Program at Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, US

**Chrystal M. Paulos**

Associate Professor, Director of Translational Research, Cutaneous Malignancies, Department of Surgery/Microbiology & Immunology, Winship Cancer Institute, Emory University, Atlanta, GA, US

# FACULTY

---

**Sandro Pignata**

Director, Medical Oncology Division of Uro-Gynecology Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Antonio Pinto**

Director of the Hematological Department, SC Director of Oncological Hematology, National Cancer Institute "Fondazione G. Pascale" Naples, Italy

**Camillo Porta**

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro"; Chief, Division of Medical Oncology, Policlinico Consorziale, Bari, Italy

**Michael A. Postow**

Memorial Sloan Kettering Cancer Center, New York, NY, US

**Giuseppe Procopio**

Director Genitourinary Medical Oncology Unit, National Cancer Institute, Milan, Italy

**Igor Puzanov**

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

**Marco Ruella**

Assistant Professor of Medicine, Hematology/Oncology Division and Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program, University Hospital of Pennsylvania, Philadelphia, PA, US

**Dirk Schadendorf**

Director & Chair, Department of Dermatology, Comprehensive Cancer Center at University Hospital, Essen, Germany

**Richard Scolyer**

Co-Medical Director, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital; Professor Central Clinical School, University of Sydney, Sydney, Australia; Conjoint Professor, Central Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

**Padmanee Sharma**

Professor, Departments of Genitourinary Medical Oncology and Immunology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, US

**Jeffrey A. Sosman**

Professor, Medicine, Hematology Oncology Division, Feinberg School of Medicine, Northwestern University, Chicago, IL, US

**Inge Marie Svane**

Professor, Director, National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

**Janis M. Taube**

Director, Division of Dermatopathology, Professor of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, US

**E.C.M.***Commissione Nazionale Formazione Continua*

## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Immunotherapy Bridge congress has been accredited (ID CME 334885) with 22,5 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare disease", belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, nurses.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check);
2. Complete the CME test by answering at least 75% of the questions correctly
3. Complete the evaluation form

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.



Immunotherapy Bridge is sponsored by an unrestricted grant from:

---

PLATINUM SPONSOR

**SANOFI** GENZYME  | **REGENERON**

GOLD SPONSOR

 **Bristol Myers Squibb™**

SILVER SPONSOR

 **BeiGene**

 **MSD**

SPONSOR

**AstraZeneca** 

 **Incyte**

 **Lunaphore**  
technologies

**MERCK**

 **Roche**

  
**SUN**  
PHARMA